Abbisko Cayman Limited
2256.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.66B
Close$
$-5.64
171.5% downside
Current Fair Value
171.5% downsideOvervalued by 171.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.66 Billion |
|---|---|
| Enterprise Value | $5.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.09 |
| Beta | 1.17 |
| Outstanding Shares | 631,095,134 |
Return
| Return on Equity | -21.41% |
|---|---|
| Return on Assets | -17.31% |
| Return on Invested Capital | -23.76% |
Valuation & Multiples
| P/E Ratio | -9.08 |
|---|---|
| PEG | 5.71 |
| Price to Sales | - |
| Price to Book Ratio | 2.63 |
| Enterprise Value to Revenue | 53.96 |
| Enterprise Value to EBIT | -10.13 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$57.73 M
Average shareholder expectationNext Earnings Call
Expected Date
March 18, 2027
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$109.64 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Abbisko Cayman Limited
286 employees
CEO: Yao-Chang Xu Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology ...